ClinicaliQ Trial Snapshot
- A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis — Recruiting • Phase II • Cardiology / Cardiovascular • NCT05646381.
- What is being tested: Pelacarsen (TQJ230), a subcutaneous antisense oligonucleotide that lowers lipoprotein(a), is being evaluated against placebo to determine whether reducing Lp(a) levels can slow the progression of calcific aortic valve stenosis (CAVS).
- Patient eligibility overview: The trial enrolls patients with established calcific aortic valve stenosis and elevated lipoprotein(a) levels; specific inclusion criteria typically require measurable aortic valve disease on imaging and baseline Lp(a) concentrations above defined thresholds.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Eligibility Snapshot
- : * Male and female ≥50 to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.